Literature DB >> 12972509

Distinctive response of naïve lymphocytes from cord blood to primary activation via TCR.

Elisabet Cantó1, Jose Luis Rodriguez-Sanchez, Silvia Vidal.   

Abstract

Umbilical cord blood (UCB) is now being considered an alternative to bone marrow for restoring hematopoiesis after myeloablative therapy. The lower risk of acute and chronic graft-versus-host disease in patients who received UCB cells seems related to the nature of UCB-T cells. Phenotypically, UCB-CD3+ cells are mostly naive (CD45RA+) and represent a transitional population between thymocytes and adult T cells. We examined the immune reactivity of highly purified, negatively selected CD4+CD45RA+ cells by mimicking activation via T cell receptor (TCR). All experiments included the extensively characterized adult peripheral blood (APB) cells as reference. On the contrary to APB, naive UCB-CD4+ cells were able to proliferate with anti-CD3 stimulation alone. With addition of interleukin (IL)-2 or costimulatory signal, both populations reached similar proliferation. Forty-eight hours after anti-CD3 stimulation, CD4+CD45RA+ from UCB, but not APB, showed characteristic blastic morphology and significant expression of CD25 on the surface. A low concentration of IL-2 was detected at 24 h by anti-CD3-stimulated UCB CD4+CD45RA+, which rapidly disappeared. By 72 h after activation, CD4+CD45RA+ UCB cells showed extensive apoptosis, whereas CD4+CD45RA+ APB cells showed low levels of apoptosis. Using RNase protection assay, we observed that CD95L levels were significantly higher in naive CD4+ cells from UCB than from APB after activation. However, neutralizing Fas-Fc protein was unable to inhibit anti-CD3-induced apoptosis, suggesting that this was a CD95-independent mechanism. These results indicate that UCB-CD4+CD45RA+ cells are able to start proliferating as a result of early IL-2 production after TCR engagement alone, but probably, as a result of the consumption of this IL-2, they undergo cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972509     DOI: 10.1189/jlb.0303098

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  13 in total

Review 1.  Umbilical cord blood immunology: relevance to stem cell transplantation.

Authors:  Syh-Jae Lin; Dah-Chin Yan; Yen-Chang Lee; Hsiu-Shan Hsiao; Pei-Tzu Lee; Yu-Wen Liang; Ming-Ling Kuo
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 2.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

3.  Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease.

Authors:  M Paz Morante; J Briones; E Canto; H Sabzevari; R Martino; J Sierra; J L Rodriguez-Sanchez; S Vidal
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.

Authors:  Patrick J Hanley; Sharon Lam; Elizabeth J Shpall; Catherine M Bollard
Journal:  J Vis Exp       Date:  2012-05-07       Impact factor: 1.355

5.  Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Authors:  Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

6.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

Review 7.  Challenges in vaccination of neonates, infants and young children.

Authors:  Michael E Pichichero
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

8.  Cord blood leptin levels of healthy neonates are associated with IFN-γ production by cord blood T-cells.

Authors:  Athanasia Mouzaki; Ioannis Panagoulias; George Raptis; Evagellia Farri-Kostopoulou
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

9.  Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT.

Authors:  L Li; H T Kim; A Nellore; N Patsoukis; V Petkova; S McDonough; I Politikos; S Nikiforow; R Soiffer; J H Antin; K Ballen; C Cutler; J Ritz; V A Boussiotis
Journal:  Blood Cancer J       Date:  2014-01-17       Impact factor: 11.037

10.  Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells.

Authors:  Kate Milward; Fadi Issa; Joanna Hester; Daniel Figueroa-Tentori; Alejandro Madrigal; Kathryn J Wood
Journal:  Transplantation       Date:  2013-01-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.